EQS-News: Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
|
EQS-News: Epigenomics AG
/ Key word(s): Personnel
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all assets of the Company to New Day Diagnostics LLC. Dr. Helge Lubenow, Chairwoman of the Supervisory Board of Epigenomics AG, thanked Jens Ravens on behalf of the entire Supervisory Board: “Jens Ravens accompanied the company during a very difficult phase and in particular made significant contributions to secure the continued existence of Epigenomics AG, both through the restructuring initiated since the beginning of 2023 and through the sale of almost all of the company's assets to New Day Diagnostics LLC. As proposed by the Executive and Supervisory Board, the Extraordinary Shareholders’ Meeting on September 11, 2023 approved the sale of nearly all assets to NDD with an overwhelming majority. The Supervisory Board considers the sale as the most promising way to create value for our shareholders in the current situation. We deeply regret the departure of Jens Ravens and wish him all the best for the future.” As of February 2022, Jens Ravens initially served as Chief Financial Officer and was, since the departure of CEO Greg Hamilton on June 30, 2023 until January 31, 2024, sole member of the Executive Board of Epigenomics AG. As of May 1, 2024, Hansjörg Plaggemars will manage the company as sole member of the Executive Board.
Contact: Investor Relations
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
30.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Epigenomics AG |
| Bertha-Benz-Straße 5 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A37FT41 |
| WKN: | A37FT4 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1893193 |
| End of News | EQS News Service |
|
|
1893193 30.04.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 1,53 | 1,13 | 0,84 | 6,20 | 0,49 | 0,34 | 0,00 | |
| EBITDA1,2 | -12,78 | -14,16 | -11,09 | -1,94 | -11,30 | -2,91 | 0,00 | |
| EBITDA-Margin3 | -835,29 | -1.253,10 | -1.320,24 | -31,29 | -2.306,12 | -855,88 | 0,00 | |
| EBIT1,4 | -12,90 | -14,67 | -11,63 | -2,35 | -12,05 | -4,50 | 0,00 | |
| EBIT-Margin5 | -843,14 | -1.298,23 | -1.384,52 | -37,90 | -2.459,18 | -1.323,53 | 0,00 | |
| Net Profit (Loss)1 | -12,69 | -17,02 | -11,69 | -2,43 | -12,02 | -4,46 | 0,00 | |
| Net-Margin6 | -829,41 | -1.506,20 | -1.391,67 | -39,19 | -2.453,06 | -1.311,77 | 0,00 | |
| Cashflow1,7 | -10,35 | -13,51 | -9,57 | -4,15 | -12,02 | -5,71 | 0,00 | |
| Earnings per share8 | -75,20 | -73,00 | -40,40 | -4,40 | -14,80 | -5,15 | -3,00 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Epigenomics | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A37FT4 | DE000A37FT41 | AG | 0,97 Mio € | 19.07.2004 | 9F4MG9F8+6P | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -0,99 | 0,00 | 0,00 | -0,02 | -0,12 | -0,17 | 2,87 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 29.05.2024 | 30.09.2024 | 14.03.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +10,41% | +5,23% | -40,32% | -40,80% | -99,92% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
